Edition:
United Kingdom

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

1.55USD
11 Dec 2017
Change (% chg)

$-0.03 (-1.59%)
Prev Close
$1.58
Open
$1.60
Day's High
$1.60
Day's Low
$1.52
Volume
22,019
Avg. Vol
60,499
52-wk High
$6.98
52-wk Low
$0.50

Chart for

About

Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition,... (more)

Overall

Beta: 2.02
Market Cap(Mil.): $43.07
Shares Outstanding(Mil.): 20.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Pulmatrix posts Q3 net loss of $0.22 per share

* Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials

09 Nov 2017

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

06 Sep 2017

BRIEF-Pulmatrix says generated no revenue in Q2 of 2017

* Pulmatrix provides 2017 company year-to-date highlights and q2 2017 updated financials

04 Aug 2017

BRIEF-Pulmatrix to pay Respivert up-front, non-refundable license fee of $1 mln

* Pulmatrix - will pay Respivert up-front, non-refundable license fee of $1 million in partial consideration for rights granted by respivert to company - sec filing

13 Jun 2017

BRIEF-Pulmatrix licenses novel drug candidates from Respivert

* Pulmatrix licenses novel drug candidates from Respivert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.

13 Jun 2017

Earnings vs. Estimates